Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis have?
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis has 961 citations in the OpenAlex counts ScholarIQ stores.
When was Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis published?
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis has 2017 year in the ScholarIQ index.
What is the open-access status of Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis?
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis has bronze oa status in the ScholarIQ index.
What is the DOI of Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis?
The DOI for Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis is on the source record.
What is the PMID of Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis?
The PMID for Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis is on the source record.
What is the OpenAlex record for Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis?
The OpenAlex for Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis is on the source record.